Skip to main content

Advertisement

SpringerLink
Log in

VIP, From Gene to Behavior and Back: Summarizing my 25 Years of Research

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Vasoactive intestinal peptide (VIP) is an interesting example of a 28-amino acid neuropeptide that is abundantly expressed in discrete brain regions/neurons and hence may contribute to brain function. This short review summarizes my own point of view and encompasses 25 years of work and over 100 publications targeting the understanding of VIP production and biological activity. The review starts with our original cloning of the VIP gene, it then continues to discoveries of regulation of VIP synthesis and the establishment of the first VIP transgenic mice. The review ends with the identification of novel VIP analogs that helped decipher VIP’s important role during development, in regulation of the biological clock(s) and diurnal rhythms, sexual activity, learning and memory as well as social behavior, and cancer. This review cites only articles that I have coauthored and gives my own perspective of this exciting ever-growing field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  • Agoston, D. V., Eiden, L. E., Brenneman, D. E., & Gozes, I. (1991). Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures. Brain Research. Molecular Brain Research, 10, 235–240.

    PubMed  CAS  Google Scholar 

  • Ashur-Fabian, O., Giladi, E., Brenneman, D. E., & Gozes, I. (1997). Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. Journal of Molecular Neuroscience, 9, 211–222.

    PubMed  CAS  Google Scholar 

  • Ashur-Fabian, O., Giladi, E., Furman, S., Steingart, R. A., Wollman, Y., Fridkin, M., et al. (2001). Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neuroscience Letters, 307, 167–170.

    PubMed  CAS  Google Scholar 

  • Ashur-Fabian, O., Perl, O., Lilling, G., Fridkin, M., & Gozes, I. (1999). SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. Peptides, 20, 629–633.

    PubMed  CAS  Google Scholar 

  • Avidor, R., Eilam, R., Malach, R., & Gozes, I. (1989). VIP-mRNA is increased in hypertensive rats. Brain Research, 503, 304–307.

    PubMed  CAS  Google Scholar 

  • Baldino, F. Jr., Fitzpatrick-McElligott, S., Gozes, I., & Card, J. P. (1989). Localization of VIP and PHI-27 messenger RNA in rat thalamic and cortical neurons. Journal of Molecular Neuroscience, 1, 199–207.

    PubMed  CAS  Google Scholar 

  • Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., et al. (1999). Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. Journal of Neurochemistry, 72, 1283–1293.

    PubMed  CAS  Google Scholar 

  • Bassan, M., Zamostiano, R., Giladi, E., Davidson, A., Wollman, Y., Pitman, J., et al. (1998). The identification of secreted heat shock 60-like protein from rat glial cells and a human neuroblastoma cell line. Neuroscience Letters, 250, 37–40.

    PubMed  CAS  Google Scholar 

  • Blondel, O., Collin, C., McCarran, W. J., Zhu, S., Zamostiano, R., Gozes, I., et al. (2000). A glia-derived signal regulating neuronal differentiation. Journal of Neuroscience, 20, 8012–8020.

    PubMed  CAS  Google Scholar 

  • Bodner, M., Fridkin, M., & Gozes, I. (1985). Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proceedings of National Academy of Sciences United States America, 82, 3548–3551.

    CAS  Google Scholar 

  • Brenneman, D. E., Glazner, G., Hill, J. M., Hauser, J., Davidson, A., & Gozes, I. (1998a). VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Annals of the New York Academy of Sciences, 865, 207–212.

    PubMed  CAS  Google Scholar 

  • Brenneman, D. E., & Gozes, I. (1996). A femtomolar-acting neuroprotective peptide. Journal of Clinical Investigation, 97, 2299–2307.

    PubMed  CAS  Google Scholar 

  • Brenneman, D. E., Hauser, J., Neale, E., Rubinraut, S., Fridkin, M., Davidson, A., et al. (1998b). Activity-dependent neurotrophic factor: structure–activity relationships of femtomolar-acting peptides. Journal of Pharmacology and Experimental Therapeutics, 285, 619–627.

    PubMed  CAS  Google Scholar 

  • Brenneman, D. E., Hill, J. M., Glazner, G. W., Gozes, I., & Phillips, T. W. (1995). Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. International Journal of Developmental Neuroscience, 13, 187–200.

    PubMed  CAS  Google Scholar 

  • Brenneman, D. E., Hill, J. M., Gozes, I., & Phillips, T. M. (1996). Vasoactive intestinal peptide releases interleukin-1 from astrocytes. Annals of the New York Academy of Sciences, 805, 280–287, discussion 287–289.

    PubMed  CAS  Google Scholar 

  • Brenneman, D. E., Phillips, T. M., Festoff, B. W., & Gozes, I. (1997). Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. Annals of the New York Academy of Sciences, 814, 167–173.

    PubMed  CAS  Google Scholar 

  • Brenneman, D. E., Phillips, T. M., Hauser, J., Hill, J. M., Spong, C. Y., & Gozes, I. (2003). Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides, 37, 111–119.

    PubMed  CAS  Google Scholar 

  • Brenneman, D. E., Schultzberg, M., Bartfai, T., & Gozes, I. (1992). Cytokine regulation of neuronal survival. Journal of Neurochemistry, 58, 454–460.

    PubMed  CAS  Google Scholar 

  • Card, J. P., Fitzpatrick-McElligott, S., Gozes, I., & Baldino, F. Jr. (1988). Localization of vasopressin-, vasoactive intestinal polypeptide-, peptide histidine isoleucine- and somatostatin-mRNA in rat suprachiasmatic nucleus. Cell and Tissue Research, 252, 307–315.

    PubMed  CAS  Google Scholar 

  • Chew, L. J., Burke, Z. D., Morgan, H., Gozes, I., Murphy, D., & Carter, D. A. (1997). Transcription of the vasoactive intestinal peptide gene in response to glucocorticoids: differential regulation of alternative transcripts is modulated by a labile protein in rat anterior pituitary. Molecular and Cellular Endocrinology, 130, 83–91.

    PubMed  CAS  Google Scholar 

  • Dangoor, D., Biondi, B., Gobbo, M., Vachutinski, Y., Fridkin, M., Gozes, I., et al. (2008). Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. Journal of Peptide Science, 14, 321–328.

    PubMed  CAS  Google Scholar 

  • Dangoor, D., Giladi, E., Fridkin, M., & Gozes, I. (2005). Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides, 26, 2579–2584.

    PubMed  CAS  Google Scholar 

  • Dangoor, D., Rubinraut, S., Fridkin, M., & Gozes, I. (2006). Novel extended and branched N-terminal analogs of VIP. Regulatory Peptides, 137, 42–49.

    PubMed  CAS  Google Scholar 

  • Dangoor, D., Rubinraut, S., Fridkin, M., & Gozes, I. (2007). Novel analogs of VIP with multiple C-terminal domains. Peptides, 28, 1622–1630.

    PubMed  CAS  Google Scholar 

  • Davidson, A., Moody, T. W., & Gozes, I. (1996). Regulation of VIP gene expression in general. Human lung cancer cells in particular. Journal of Molecular Neuroscience, 7, 99–110.

    PubMed  CAS  Google Scholar 

  • Delgado, M., Munoz-Elias, E. J., Kan, Y., Gozes, I., Fridkin, M., Brenneman, D. E., et al. (1998). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. Journal of Biological Chemistry, 273, 31427–31436.

    PubMed  CAS  Google Scholar 

  • Dibbern, D. A. Jr., Glazner, G. W., Gozes, I., Brenneman, D. E., & Hill, J. M. (1997). Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. Journal of Clinical Investigation, 99, 2837–2841.

    PubMed  CAS  Google Scholar 

  • Eilam, R., Davidson, A., Gozes, I., & Segal, M. (1999). Locomotor activity causes a rapid up-regulation of vasoactive intestinal peptide in the rat hippocampus. Hippocampus, 9, 534–541.

    PubMed  CAS  Google Scholar 

  • Gelber, E., Granoth, R., Fridkin, M., Dreznik, Z., Brenneman, D. E., Moody, T. W., et al. (2001). A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer, 92, 2172–2180.

    PubMed  CAS  Google Scholar 

  • Giladi, E., Hill, J. M., Dresner, E., Stack, C. M., & Gozes, I. (2007). Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. Journal of Molecular Neuroscience, 33, 278–283.

    PubMed  CAS  Google Scholar 

  • Giladi, E., Shani, Y., & Gozes, I. (1990). The complete structure of the rat VIP gene. Brain Research. Molecular Brain Research, 7, 261–267.

    PubMed  CAS  Google Scholar 

  • Glazer, R., & Gozes, I. (1994). Diurnal oscillation in vasoactive intestinal peptide gene expression independent of environmental light entraining. Brain Research, 644, 164–167.

    PubMed  CAS  Google Scholar 

  • Glowa, J. R., Panlilio, L. V., Brenneman, D. E., Gozes, I., Fridkin, M., & Hill, J. M. (1992). Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Research, 570, 49–53.

    PubMed  CAS  Google Scholar 

  • Gozes, I. (2007a). The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley. Expert Opinion on Therapeutic Targets, 11, 733–736.

    PubMed  Google Scholar 

  • Gozes, I. (2007b). Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacology & Therapeutics, 114, 146–154.

    CAS  Google Scholar 

  • Gozes, I., Avidor, R., Biegon, A., & Baldino, F. Jr. (1989a). Lactation elevates vasoactive intestinal peptide messenger ribonucleic acid in rat suprachiasmatic nucleus. Endocrinology, 124, 181–186.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Avidor, R., Giladi, E., Shani, Y., McEwen, B. S., Dussaillant, M., et al. (1994b). Adrenalectomy decreases vasoactive intestinal peptide mRNA levels in the rat suprachiasmatic nucleus. Neuroscience Letters, 167, 24–28.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Avidor, R., Yahav, Y., Katznelson, D., Croce, C. M., & Huebner, K. (1987b). The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21–-6qter. Human Genetics, 75, 41–44.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Bachar, M., Bardea, A., Davidson, A., Rubinraut, S., & Fridkin, M. (1998a). Protection against developmental deficiencies by a lipophilic VIP analogue. Neurochemical Research, 23, 689–693.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Bachar, M., Bardea, A., Davidson, A., Rubinraut, S., Fridkin, M., et al. (1997). Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer’s disease. Journal of Neurobiology, 33, 329–342.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Bardea, A., Reshef, A., Zamostiano, R., Zhukovsky, S., Rubinraut, S., et al. (1996a). Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proceedings of the National Academy of Sciences of the United States of America, 93, 427–432.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Bodner, M., Shani, Y., & Fridkin, M. (1984a). Detection of mRNAs containing regulatory peptide coding sequences using synthetic oligodeoxynucleotides. Journal of Cellular Biochemistry, 26, 147–156.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Bodner, M., Shani, Y., & Fridkin, M. (1986). Structure and expression of the vasoactive intestinal peptide (VIP) gene in a human tumor. Peptides, 7(Suppl 1), 1–6.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Bodner, M., Shwartz, H., Shani, Y., & Fridkin, M. (1984b). Studies toward the biosynthesis of vasoactive intestinal peptide (VIP). Peptides, 5, 161–166.

    PubMed  CAS  Google Scholar 

  • Gozes, I., & Brenneman, D. E. (1989). VIP: molecular biology and neurobiological function. Molecular Neurobiology, 3, 201–236.

    PubMed  CAS  Google Scholar 

  • Gozes, I., & Brenneman, D. E. (1993). Neuropeptides as growth and differentiation factors in general and VIP in particular. Journal of Molecular Neuroscience, 4, 1–9.

    PubMed  CAS  Google Scholar 

  • Gozes, I., & Brenneman, D. E. (1996). Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? Journal of Molecular Neuroscience, 7, 235–244.

    PubMed  CAS  Google Scholar 

  • Gozes, Y., Brenneman, D. E., Fridkin, M., Asofsky, R., & Gozes, I. (1991c). A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Research, 540, 319–321.

    PubMed  CAS  Google Scholar 

  • Gozes, I., & Fridkin, M. (1992). A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model. Journal of Clinical Investigation, 90, 810–814.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Fridkin, M., & Brenneman, D. E. (1995a). A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Cellular and Molecular Neurobiology, 15, 675–687.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Fridkin, M., Hill, J. M., & Brenneman, D. E. (1999a). Pharmaceutical VIP: prospects and problems. Current Medicinal Chemistry, 6, 1019–1034.

    PubMed  CAS  Google Scholar 

  • Gozes, I., & Furman, S. (2003). VIP and drug design. Current Pharmaceutical Design, 9, 483–494.

    PubMed  CAS  Google Scholar 

  • Gozes, I., & Furman, S. (2004). Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Practice and Research. Clinical Endocrinology & Metabolism, 18, 623–640.

    CAS  Google Scholar 

  • Gozes I., Glowa J., Brenneman D. E., McCune S. K., Lee E. & Westphal H. (1993). Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. Journal of Molecular Neuroscience, 4, 185–193.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Lilling, G., Davidson, A., Bardea, A., Reshef, A., Glazer, R., et al. (1996b). Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock. Annals of the New York Academy of Sciences, 805, 159–169, discussion 169–171.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Lilling, G., Glazer, R., Ticher, A., Ashkenazi, I. E., Davidson, A., et al. (1995b). Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. Journal of Pharmacology and Experimental Therapeutics, 273, 161–167.

    PubMed  CAS  Google Scholar 

  • Gozes, I., McCune, S. K., Jacobson, L., Warren, D., Moody, T. W., Fridkin, M., et al. (1991b). An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. Journal of Pharmacology and Experimental Therapeutics, 257, 959–966.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Meltzer, E., Rubinrout, S., Brenneman, D. E., & Fridkin, M. (1989b). Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. Endocrinology, 125, 2945–2949.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Milner, R. J., Liu, F. T., Johnson, E., Battenberg, E. L., Katz, D. H., et al. (1983b). Monoclonal antibodies against vasoactive intestinal polypeptide: studies of structure and related antigens. Journal of Neurochemistry, 41, 549–555.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Morimoto, B. H., Tiong, J., Fox, A., Sutherland, K., Dangoor, D., et al. (2005). NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Reviews, 11, 353–368.

    PubMed  CAS  Google Scholar 

  • Gozes, Y., Moskowitz, M. A., Strom, T. B., & Gozes, I. (1982). Conditioned media from activated lymphocytes maintain sympathetic neurons in culture. Brain Research, 282, 93–97.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Nakai, H., Byers, M., Avidor, R., Weinstein, Y., Shani, Y., & Shows, T. B. (1987c). Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24. Somatic Cell and Molecular Genetics, 13, 305–313.

    PubMed  CAS  Google Scholar 

  • Gozes, I., O’Connor, D. T., & Bloom, F. E. (1983a). A possible high molecular weight precursor to vasoactive intestinal polypeptide sequestered into pheochromocytoma chromaffin granules. Regulatory Peptide, 6, 111–119.

    CAS  Google Scholar 

  • Gozes, I., Perl, O., Giladi, E., Davidson, A., Ashur-Fabian, O., Rubinraut, S., et al. (1999b). Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proceedings of the National Academy of Sciences of the United States of America, 96, 4143–4148.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Perl, O., Zamostiano, R., Rubinraut, S., Fridkin, M., Shochat, L., et al. (1998b). Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. Annals of the New York Academy of Sciences, 865, 266–273.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Reshef, A., Salah, D., Rubinraut, S., & Fridkin, M. (1994a). Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment. Endocrinology, 134, 2121–2125.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Schachter, P., Shani, Y., & Giladi, E. (1988). Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology, 47, 27–31.

    PubMed  CAS  Google Scholar 

  • Gozes, I., & Shani, Y. (1986). Hypothalamic vasoactive intestinal peptide messenger ribonucleic acid is increased in lactating rats. Endocrinology, 119, 2497–2501.

    Article  PubMed  CAS  Google Scholar 

  • Gozes, I., Shani, Y., Kiu, B., & Burbach, J. P. H. (1991a). Diurnal variation in vasoactive intestinal peptide messenger RNA in the suprachiasmatic nucleus of the rat. Neuroscience Research Communications, 5, 83–86.

    Google Scholar 

  • Gozes, I., Shani, Y., & Rostene, W. H. (1987a). Developmental expression of the VIP-gene in brain and intestine. Brain Research, 388, 137–148.

    PubMed  CAS  Google Scholar 

  • Gozes, I., & Tsafriri, A. (1986). Detection of vasoactive intestinal peptide-encoding messenger ribonucleic acid in the rat ovaries. Endocrinology, 119, 2606–2610.

    PubMed  CAS  Google Scholar 

  • Gozes, I., Werner, H., Fawzi, M., Abdelatty, A., Shani, Y., Fridkin, M., & Koch, Y. (1989c). Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. Journal of Molecular Neuroscience, 1, 55–61.

    PubMed  CAS  Google Scholar 

  • Granoth, R., Fridkin, M., & Gozes, I. (2000a). VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes. FEBS Letters, 475, 78–83.

    PubMed  CAS  Google Scholar 

  • Granoth, R., Fridkin, M., Rubinraut, S., & Gozes, I. (2000b). VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model. FEBS Letters, 475, 71–77.

    PubMed  CAS  Google Scholar 

  • Gressens, P., Besse, L., Robberecht, P., Gozes, I., Fridkin, M., & Evrard, P. (1999). Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. Journal of Pharmacology and Experimental Therapeutics, 288, 1207–1213.

    PubMed  CAS  Google Scholar 

  • Gressens, P., Hill, J. M., Gozes, I., Fridkin, M., & Brenneman, D. E. (1993). Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature, 362, 155–158.

    PubMed  CAS  Google Scholar 

  • Gressens, P., Hill, J. M., Paindaveine, B., Gozes, I., Fridkin, M., & Brenneman, D. E. (1994). Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. Journal of Clinical Investigation, 94, 2020–2027.

    PubMed  CAS  Google Scholar 

  • Gressens, P., Marret, S., Hill, J. M., Brenneman, D. E., Gozes, I., Fridkin, M., et al. (1997). Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. Journal of Clinical Investigation, 100, 390–397.

    PubMed  CAS  Google Scholar 

  • Harmar, A. J., Arimura, A., Gozes, I., Journot, L., Laburthe, M., Pisegna, J. R., et al. (1998). International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacological Reviews, 50, 265–270.

    PubMed  CAS  Google Scholar 

  • Hill, J. M., Glazner, G. W., Lee, S. J., Gozes, I., Gressens, P., & Brenneman, D. E. (1999b). Vasoactive intestinal peptide regulates embryonic growth through the action of activity-dependent neurotrophic factor. Annals of the New York Academy of Sciences, 897, 92–100.

    PubMed  CAS  Google Scholar 

  • Hill, J. M., Gozes, I., Hill, J. L., Fridkin, M., & Brenneman, D. E. (1991). Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides, 12, 187–192.

    PubMed  CAS  Google Scholar 

  • Hill, J. M., Hauser, J. M., Sheppard, L. M., Abebe, D., Spivak-Pohis, I., Kushnir, M., et al. (2007). Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. Journal of Molecular Neuroscience, 31, 183–200.

    PubMed  CAS  Google Scholar 

  • Hill, J. M., Lee, S. J., Dibbern, D. A. Jr., Fridkin, M., Gozes, I., & Brenneman, D. E. (1999a). Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth. Neuroscience, 93, 783–791.

    PubMed  CAS  Google Scholar 

  • Hill, J. M., Mervis, R. F., Politi, J., McCune, S. K., Gozes, I., Fridkin, M., et al. (1994). Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Annals of the New York Academy of Sciences, 739, 211–225.

    PubMed  CAS  Google Scholar 

  • Holtzman, R. L., Malach, R., & Gozes, I. (1989). Disruption of the optic pathway during development affects vasoactive intestinal peptide mRNA expression. New Biologist, 1, 215–221.

    PubMed  CAS  Google Scholar 

  • Kim, W. K., Kan, Y., Ganea, D., Hart, R. P., Gozes, I., & Jonakait, G. M. (2000). Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. Journal of Neuroscience, 20, 3622–3630.

    PubMed  CAS  Google Scholar 

  • Levy, A., Gal, R., Granoth, R., Dreznik, Z., Fridkin, M., & Gozes, I. (2002). In vitro and in vivo treatment of colon cancer by VIP antagonists. Regulatory Peptides, 109, 127–133.

    PubMed  CAS  Google Scholar 

  • Lilling, G., Wollman, Y., Goldstein, M. N., Rubinraut, S., Fridkin, M., Brenneman, D. E., et al. (1994). Inhibition of human neuroblastoma growth by a specific VIP antagonist. Journal of Molecular Neuroscience, 5, 231–239.

    PubMed  CAS  Google Scholar 

  • Moody, T. W., & Gozes, I. (2007). Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Current Pharmaceutical Design, 13, 1099–1104.

    PubMed  CAS  Google Scholar 

  • Moody, T. W., Jensen, R. T., Fridkin, M., & Gozes, I. (2002). (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. Journal of Molecular Neuroscience, 18, 29–35.

    PubMed  CAS  Google Scholar 

  • Moody, T. W., Leyton, J., Chan, D., Brenneman, D. C., Fridkin, M., Gelber, E., et al. (2001). VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer and Research Treatment, 68, 55–64.

    CAS  Google Scholar 

  • Moody, T. W., Leyton, J., Coelho, T., Jakowlew, S., Takahashi, K., Jameison, F., et al. (1997). (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells. Life Science, 61, 1657–1666.

    CAS  Google Scholar 

  • Moody, T. W., Leyton, J., Gozes, I., Lang, L., & Eckelman, W. C. (1998). VIP and breast cancer. Annals of the New York Academy of Sciences, 865, 290–296.

    PubMed  CAS  Google Scholar 

  • Moody, T. W., Walters, J., Casibang, M., Zia, F., & Gozes, Y. (2000). VPAC1 receptors and lung cancer. Annals of the New York Academy of Sciences, 921, 26–32.

    PubMed  CAS  Google Scholar 

  • Moody, T. W., Zia, F., Draoui, M., Brenneman, D. E., Fridkin, M., Davidson, A., et al. (1993). A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proceedings of the National Academy of Sciences of the United States of America, 90, 4345–4349.

    PubMed  CAS  Google Scholar 

  • Nowak, J. Z., Sedkowska, P., Zawilska, J. B., Gozes, I., & Brenneman, D. E. (2003). Antagonism of VIP-stimulated cyclic AMP formation in chick brain. Journal of Molecular Neuroscience, 20, 163–172.

    PubMed  CAS  Google Scholar 

  • Offen, D., Sherki, Y., Melamed, E., Fridkin, M., Brenneman, D. E., & Gozes, I. (2000). Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson’s disease. Brain Research, 854, 257–262.

    PubMed  CAS  Google Scholar 

  • Pilzer, I., & Gozes, I. (2006a). VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides, 27, 2867–2876.

    PubMed  CAS  Google Scholar 

  • Pilzer, I., & Gozes, I. (2006b). A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes. Annals of the New York Academy of Sciences, 1070, 484–490.

    PubMed  CAS  Google Scholar 

  • Rostene, W., Montagne, M. N., Dussaillant, M., & Gozes, I. I. (1997). Steroid Regulation of Vasoactive Intestinal Peptide (VIP). Stress, 2, 79–90.

    Article  PubMed  CAS  Google Scholar 

  • Servoss, S. J., Lee, S. J., Gibney, G., Gozes, I., Brenneman, D. E., & Hill, J. M. (2001). IGF-I as a mediator of VIP/activity-dependent neurotrophic factor-stimulated embryonic growth. Endocrinology, 142, 3348–3353.

    PubMed  CAS  Google Scholar 

  • Sigalov, E., Fridkin, M., Brenneman, D. E., & Gozes, I. (2000). VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. Journal of Molecular Neuroscience, 15, 147–154.

    PubMed  CAS  Google Scholar 

  • Steingart, R. A., Heldenberg, E., Pinhasov, A., Brenneman, D. E., Fridkin, M., & Gozes, I. (2002). A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. Life Science, 71, 2543–2552.

    CAS  Google Scholar 

  • Steingart, R. A., Solomon, B., Brenneman, D. E., Fridkin, M., & Gozes, I. (2000). VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. Journal of Molecular Neuroscience, 15, 137–145.

    PubMed  CAS  Google Scholar 

  • Wang, H. Y., Jiang, X., Gozes, I., Fridkin, M., Brenneman, D. E., & Ganea, D. (1999). Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regulatory Peptides, 84, 55–67.

    PubMed  CAS  Google Scholar 

  • Werner, H., Koch, Y., Fridkin, M., Fahrenkrug, J., & Gozes, I. (1985). High levels of vasoactive intestinal peptide in human milk. Biochemical and Biophysical Research Communications, 133, 228–232.

    PubMed  CAS  Google Scholar 

  • White, D. M., Walker, S., Brenneman, D. E., & Gozes, I. (2000). CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Research, 868, 31–38.

    PubMed  CAS  Google Scholar 

  • Wollman, Y., Blumberg, S., Spungin, A., Brenneman, D. E., Fridkin, M., Wollman, J., et al. (2002). The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase. Regulatory Peptides, 108, 175–177.

    PubMed  CAS  Google Scholar 

  • Wollman, Y., Lilling, G., Goldstein, M. N., Fridkin, M., & Gozes, I. (1993). Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells. Brain Research, 624, 339–341.

    PubMed  CAS  Google Scholar 

  • Wu, J. Y., Henins, K. A., Gressens, P., Gozes, I., Fridkin, M., Brenneman, D. E., et al. (1997). Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides, 18, 1131–1137.

    PubMed  CAS  Google Scholar 

  • Zamostiano, R., Pinhasov, A., Bassan, M., Perl, O., Steingart, R. A., Atlas, R., et al. (1999). A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neuroscience Letters, 264, 9–12.

    PubMed  CAS  Google Scholar 

  • Zawilska, J. B., Dejda, A., Niewiadomski, P., Gozes, I., & Nowak, J. Z. (2005). Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding. Journal of Molecular Neuroscience, 25, 215–224.

    PubMed  CAS  Google Scholar 

  • Zia, H., Hida, T., Jakowlew, S., Birrer, M., Gozes, Y., Reubi, J. C., et al. (1996). Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Research, 56, 3486–3489.

    PubMed  CAS  Google Scholar 

  • Zia, H., Leyton, J., Casibang, M., Hau, V., Brenneman, D., Fridkin, M., et al. (2000). (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines. Life Science, 66, 379–387.

    CAS  Google Scholar 

  • Zupan, V., Hill, J. M., Brenneman, D. E., Gozes, I., Fridkin, M., Robberecht, P., et al. (1998). Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. Journal of Neurochemistry, 70, 2165–2173.

    Article  PubMed  CAS  Google Scholar 

  • Zusev, M., & Gozes, I. (2004). Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regulatory Peptides, 123, 33–41.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

I thank my former student and current colleague and friend Dr. Sharon Furman Assaf for critical reading of this manuscript. VIP studies over the years were supported by the BSF, Bergmann Memorial Award, Neufeld Award, ISF, ISOA, NICHD and NCI intramural, Fogarty Scholar Program, the NIH-TAU student exchange program in Women Health, Fujimoto Pharmaceutical Corp., Bayer, Israel Cancer Research Fund, Tel Aviv University Cancer Center, Johnson & Johnson (COSAT), and the Lily and Avraham Gildor Chair for the Investigation of Growth Factors. Studies were made possible by excellent worldwide collaborations and dedicated staff members, students and postdoctoral fellows (>50) over a quarter of a century. Special thanks are to my long-time friends and colleagues that traveled with me in the VIP field over many years and I will mention just a few, Dr. Yehoshua Gozes, Dr. Douglas E. Brenneman, Dr. Joanna M. Hill, Dr. Terry W. Moody, Dr. Mati Fridkin, Dr. Eliezer Giladi, Dr. Inbar Pilzer, and Dr. David Dangoor. I am currently serving as the incumbent of the Lily and Avraham Gildor Chair for the Investigation of Growth Factors, the Director of the Adams Super Center for Brain Studies, the LEG fMRI Institute and the Elton Laboratory for Molecular Neuroendocrinology at Tel Aviv University. I also serve as the Chief Scientific Officer of Allon Therapeutics Inc (www.allontherapeutics.com).

Author information

Authors and Affiliations

  1. The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Adams Super Center for Brain Studies, The Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel

    Illana Gozes

Authors
  1. Illana Gozes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Illana Gozes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gozes, I. VIP, From Gene to Behavior and Back: Summarizing my 25 Years of Research. J Mol Neurosci 36, 115–124 (2008). https://doi.org/10.1007/s12031-008-9105-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-008-9105-3

Keywords

Search

Navigation